Olympus has signed a definitive agreement to acquire Arc Medical Design Limited (Arc Medical Design), a subsidiary of Norgine BV. The acquisition allows Olympus to expand its offering in gastrointestinal therapeutic devices and the development of advanced colonoscopy tools through mergers and acquisitions opportunities, as well as through research and development with the overarching goal of improving early detection and treatment of colorectal cancer (CRC).
Under the agreement Olympus will acquire Arc Medical Design and obtain full rights to its suite of innovative medical products. Olympus will convert its current exclusive distribution rights of Endocuff Vision to a full acquisition of the Endocuff range of products, which also includes Endocuff, Endocuff Glide and Enterocufff, as well as Wide-Eye Polytrap and several products currently in development.
By acquiring Arc Medical Design, Olympus is assuming worldwide responsibility for design, manufacturing, distribution and business strategy for the product portfolio with an immediate effect. It will further enable the company to improve clinical outcomes, reduce overall costs and enhance quality of life for patients.
“It is a great pleasure to announce our acquisition of Arc Medical Design”, said Mike Callaghan, Vice President/General Manager of Global GI EndoTherapy Business Unit at Olympus. “Endocuff Vision has been a pivotal tool in our EndoTherapy portfolio, and we are delighted to expand our product portfolio to include the entire Endocuff family.”
The Endocuff Vision is a device attached to the distal end of a colonoscope, designed to maintain and maximise the viewable mucosa during endoscopic therapy by manipulating colonic folds. A single row of flexible arms everts and flattens folds to provide an enhanced view of the entire colon and to decrease the polyp miss rate. Through its unique design, Endocuff Vision can manipulate large folds, anchor the scope tip during loop reduction and stabilise during complex procedures, such as a polypectomy.
Data has shown a colonoscopy with Endocuff technology can increase the adenoma detection rate (ADR) by up to 11% compared to a standard colonoscopy. Research shows that, for every 1% increase in ADR, there is a 3% decrease in CRC risk. Higher detection rates and more accurate diagnosis could, therefore, help reduce the number of deaths from preventable digestive cancers, such as CRC.
“The acquisition of Arc Medical Design not only further enhances our expertise in medical technology and strengthens our global leadership in endoscopy, it also serves our purpose to make people’s lives healthier, safer and more fulfilling.”